Trial · NCT04969887
Combination Immunotherapy in Rare Cancers Under InvesTigation
NCT04969887, Phase 2, Active not recruiting, Olivia Newton-John Cancer Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination Immunotherapy in Rare Cancers Under InvesTigation. Trials, record NCT04969887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04969887
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination Immunotherapy in Rare Cancers Under InvesTigation
- NCT number
- NCT04969887
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 240 participants, actual
- Lead sponsor
- Olivia Newton-John Cancer Research Institute
- Conditions
- Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor
- Interventions
- Ipilimumab, Nivolumab
- First posted
- 2021-07-21
- Last updated
- 2026-02-27
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Confirm the clinical efficacy of ipi/nivo in rare cancer histotypes which have demonstrated to be responsive to the regimen in the CA209-538 study. | At 12 weeks following registration then as assessed by standard care until progression. | Clinical benefit rate for whole population (CR (complete response)+PR (partial response) assessed by radiographic evidence in accordance with RECIST 1.1 criteria |
| Primary | Determine the proportion of participants with progression free survival at 6 months | Enrolment on study until 6 months. | Progression-free survival based on clinical or radiographic evidence of progressive disease according to RECIST 1.1 criteria at 6 months. |
| Secondary | To confirm the overall survival of participants receiving ipi/nivo in rare cancer histotypes which have demonstrated to be responsive to the regimen | From date of enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Quantification of OS. |
| Secondary | To confirm the progression free survival of participants receiving ipi/nivo in rare cancer histotypes which have demonstrated to be responsive to the regimen | From date of enrolment until the date of first documented progression up to 5 years. | Quantification of PFS |
| Secondary | Quantification of treatment related toxicities to ipi/nivo according to CTCAE V5.0 | From 1st dose until 30 days following last dose [up to max 2 years + 30 days]. | Quantification of treatment related toxicities according to CTCAE V5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04969887
GET https://conductscience.org/api/trials/v1/NCT04969887/registered